WallStSmart

Airsculpt Technologies Inc (AIRS)vsMerck & Company Inc (MRK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 44066% more annual revenue ($66.57B vs $150.72M). MRK leads profitability with a 4.8% profit margin vs -7.8%. AIRS earns a higher WallStSmart Score of 38/100 (F).

AIRS

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 3.5
Piotroski: 2/9Altman Z: 0.75

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AIRSUndervalued (+34.4%)

Margin of Safety

+34.4%

Fair Value

$3.23

Current Price

$2.13

$1.10 discount

UndervaluedFair: $3.23Overvalued
MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.76

$60.92 premium

UndervaluedFair: $82.84Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AIRS2 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
200.0%10/10

Earnings expanding 200.0% YoY

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

AIRS4 concerns · Avg: 2.5/10
Market CapQuality
$173.03M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-11.2%2/10

ROE of -11.2% — below average capital efficiency

Revenue GrowthGrowth
-2.5%2/10

Revenue declined 2.5%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : AIRS

The strongest argument for AIRS centers on Price/Book, EPS Growth.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : AIRS

The primary concerns for AIRS are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

AIRS profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

AIRS carries more volatility with a beta of 2.29 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

AIRS scores higher overall (38/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Airsculpt Technologies Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Airsculpt Technologies Inc (AIRS) is at the forefront of the aesthetic medical technology sector, specializing in its proprietary AirSculpt® procedure, which sets a new standard for minimally invasive body contouring while prioritizing patient safety and comfort. The company is aggressively expanding its network of licensed practitioners and utilizing innovative technologies to solidify its competitive advantage in the rapidly growing non-invasive cosmetic treatment market. With rising global demand for aesthetic solutions, Airsculpt is well-positioned to capture market share and broaden its service offerings, driving robust growth and long-term value for its investors.

Visit Website →

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?